Applied Biosystems Expands Sequencing-based RNA Analysis Solutions Portfolio 27 August 2008 Applied Biosystems announced the development of a sequencing-based molecular tool for the genomic analysis of whole transcriptomes, the vast collection of RNAs transcribed from a genome. This technology provides detailed characterization of expressed protein-encoding genes, identifies many non-coding RNAs, and includes sample multiplexing capability.
Improved bone marrow differential method with DRAQ5 27 August 2008 In the May 2008 issue of the Am. J. Clin. Path. Allan et al. describe an exciting new method which gives improved flow cytometric analysis of clinical bone marrow aspirates for the evaluation of hematolymphoid neoplasias.
Alcohol Consumption Can Cause Too Much Cell Death, Fetal Abnormalities 26 August 2008 The initial signs of fetal alcohol syndrome are slight but classic: facial malformations such as a flat and high upper lip, small eye openings and a short nose.
Novosom AG acquires exclusive license from Isis Pharmaceuticals, Inc. for CD40-targeted antisense inhibitors 26 August 2008 Novosom AG today announced that it has acquired an exclusive, worldwide license from Isis Pharmaceuticals to access certain antisense inhibitors targeting CD40 mRNA for a number of indications.
WiCell Research Institute Launches New Stem Cell Bank 25 August 2008 New bank starts operation with three iPS cell lines from Thomson lab at UW-Madison.
Challenging the X-MAN™: Horizon Discovery Sign Evaluation Agreement with Leading Cancer Pharma 25 August 2008 The agreement covers an eight month broad evaluation of a panel of seven X-MAN cell lines.
Embryome Sciences Licenses Virus-Free iPS and Embryonic Stem Cell Differentiation Technology 22 August 2008 The technology licensed from the Advanced Cell Technology is for the commercialization of products in human therapeutics and diagnostic product markets.
ArunA Biomedical Announces Exclusive Worldwide Technology License Agreement with University of Georgia 20 August 2008 The license agreement will enable the company to commercialize human embryonic stem cell derived mesenchymal cells.